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termabortionappearedsufficient;nevertheless,somedisclosures
mayhavebeenmissed.Whether the lowproportionofhospitals
that did not cite health care restrictions reflects a lack of trans-
parencyornonadherence to thedirectives isunknown. Inaddi-
tion, someof thehospitals that cited thedirectivesmayprovide
reproductiveservices.Howoftenpatientsconsulthospitalweb-
sites for such information is also unknown.
Greater transparency about religious affiliation and care
restrictions may allow patients to make more informed
choices.1 In the state of Washington, hospitals must provide
their reproductive health and end-of-life care policies on
publicly available websites.6 Further research on the effect of
this initiative on patient satisfaction and health care choices
is warranted.
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COMMENT&RESPONSE
Challenges in Research on Suicide Prevention
To the Editor In aViewpoint,Drs Sisti and Joffe1 expressed con-
cern that interventions to reduce suicide have not been well
studied in clinical trials andproposed inclusionof actively sui-
cidal individuals in trials. The US Food and Drug Administra-
tion (FDA)provides regulatory adviceon clinical trials for psy-
chiatric drug development. We wish to comment on several
issues in the article.
In the recentFDAdraft guidance to industryonantidepres-
santdrugdevelopment,2 inclusionofpatientswithsuicidal ide-
ationandbehavior inclinical trialswasencouraged.Other con-
ditions with increased risk of suicidal ideation and behavior,
including bipolar disorder and schizophrenia, were not men-
tioned because separate guidances are pending; however,
the FDA agrees with the inclusion of such patients in trials.
To theextentpossible, studypopulations should reflect the full
severity range of patients encountered in clinical practice.
However, we do not believe that including patients with
suicidal ideationorbehavior in clinical trials obviates theneed
toprovide standard-of-care treatment for acutely suicidal pa-
tients. In apreviousFDAguidance,3 itwas recommended that
patientswith suicidal ideation (ie, Columbia-Suicide Severity
Rating Scale4 score ≥4) should be excluded or discontinued
frommostclinical trials so that theycanreceive immediatepsy-
chiatric intervention. We have additional concerns about in-
cludingpatientswith suicidal ideationor behavior in trials for
nonpsychiatric indications because psychiatricmonitoring is
limited in these settings.Nevertheless, such inclusionmaybe
possible with appropriate precautions.
In recent years, some drug development programs have
proposed reductionof suicidal ideationor behavior as a treat-
ment indication. Such studies are ethically supportable if pa-
tients receive standard-of-care interventions based on sever-
ity of suicidal ideationor behavior, although theymay require
inpatient settings. Unlike the authors, we believe that ad-
verse events related to suicidal ideationor behavior shouldbe
reported as adverse events in these studies, but only if the
events are more severe than at baseline. This recommenda-
tionwouldpermit appropriate safetymonitoringwhile avoid-
ingoverreporting.Moreover, events reportedasadverseevents
could still be included in the efficacy analyses.
As the authors noted, death due to suicide is not a practi-
cable primary end point for trials of interventions to reduce
suicidal ideation or behavior. The FDA is open to considering
surrogate end points to support indications for treatment
of suicidal ideation or behavior. We agree that data on sui-
cidal behavior and deaths should be collected with suicidal
ideation because the relationship between them is not yet
fully characterized.
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To the Editor Drs Sisti and Joffe1 described challenges in con-
ductingresearchonsuicide.Weagree thatsuchresearchshould
include individualswith suicidal behavior and that suicide at-
tempts anddeath are appropriate outcomes for trials.We also
agree that conceptualizing the outcome of suicide as an ad-
verse eventmight trigger objections by regulatory bodies that
jeopardize the feasibility of such investigations.
We disagree, however, that the zero suicidemodel might
“paradoxicallyconstrain”research.1Aspreviouslydescribed,2,3
the zero suicide model is a comprehensive quality improve-
ment approach that organizations can use to improve health
care delivery. The zero suicide model consists of 3 essential
components: a conviction that ideal health care is attainable,
a road map to achieve that vision, and requisite expertise in
systems engineering to rapidly achieve zero suicides.
Following its introduction in 1966,4 theconceptof zerode-
fects spread to industries throughout the world, and re-
cently, innovating to zero was called 1 of 10 megatrends for
innovation.5 High-reliability organizations aggressively pur-
sue perfection, an approach that has driven commercial avia-
tion to achieve remarkable levels of safety. Twenty years ago,
theHenry FordHealth Systemadopted this approach, setting
goals for mental health care and achieving an 80% reduction
in suicides, which was maintained over a decade.3
In our view, the success of the zero suicidemodel depends
ona just culture, one that viewserrors ornearmisses as system
failures from which to learn and rapidly improve. In response
to defects, a just culture asks “What happened and how?”, not
“Whodid it?”A just cultureseeks recovery, restoration,and im-
provement, not blame, punishment, or retribution.
Thus,wedisagree thatacorollaryof thezerosuicidemodel
“is that every suicide represents a culpable failure on the part
of health professionals.”1 Quite the contrary, the zero suicide
model views a suicide as a system defect that provides an es-
sential opportunity for learning and rapid improvement. This
approach is constructive andproductive andwill not only im-
prove care but enable clinical research. The Substance Abuse
and Mental Health Services Administration and the National
Institute of Mental Health have recently provided funding to
study the effectiveness of the zero suicide model.
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In Reply We are gratified to know that the FDA is developing
guidance that supports inclusion of individuals with suicidal
ideation or behavior associated with serious mental ill-
nesses, including schizophrenia andbipolar disorder, in clini-
cal trials. We agree that trial participants with acute suicidal
ideation or behavior, including those in the control groups of
clinical trials evaluating suicidal ideationorbehavior as anend
point, be provided with standard-of-care (including emer-
gency) interventions or with investigational approaches hy-
pothesized tobe as goodasor better than the standardof care.
However,mandatingparticipant exclusionwhen suicidal ide-
ation or behavior passes a predetermined threshold is a step
backward: drawing conclusions about new treatments for the
population most at risk would be impossible.
The question of whether worsening of suicidal ideation
or behavior should be reported as an adverse event merits
further discussion for at least 2 reasons: (1) the importance of
distinguishing between lack of efficacy of an intervention
and its toxicity and (2) the risk that sponsors, data and safety
monitoring committees, or institutional review boards will
take actions because of unjustified concerns about toxicity
that undermine ongoing trials.
The issue of nonpsychiatric research involving suicidal
participants is an important one but is beyond the scope of
our argument.
We appreciate the clarification offered by Dr Coffey and
colleagues,whoprovide additional details about the aimsand
missionof the zero suicidemodel and the importanceof a just
culture in ensuring safety. Aswe noted in our article, the zero
suicide model is a laudable goal in clinical settings.1 Further-
more, we strongly agree that a just culture and a nonpunitive
approach are essential to understanding root causes and pre-
venting sentinel events in clinical care.
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Our concern is that the zero suicidemodelmight be inap-
propriately applied in research settings in which the aim is to
identify evidence-based suicide reduction interventions that
can bring the zero suicide vision closer. Engaging in such re-
search entails a forthright acknowledgment that somepartici-
pantswill attempt suicide and that despite investigators’ best
efforts, someof those attemptsmaybe successful. It is impor-
tant to clarify that such events, assuming adherence to pro-
tocol and standards of care, do not represent culpable fail-
ures on behalf of investigators or institutions.
Dominic A. Sisti, PhD
Steven Joffe, MD, MPH
Author Affiliations:Department of Medical Ethics and Health Policy, Perelman
School of Medicine at the University of Pennsylvania, Philadelphia.
Corresponding Author:Dominic A. Sisti, PhD, Division of Medical Ethics,
Department of Medical Ethics and Health Policy, Perelman School of Medicine
at the University of Pennsylvania, 423 Guardian Dr, Blockley Hall, Philadelphia,
PA 19104 (sistid@upenn.edu).
Conflictof InterestDisclosures:DrSisti reportedreceivingagrantfromtheThomas
ScattergoodBehavioralHealth Foundation.Noother disclosureswere reported.
1. Sisti DA, Joffe S. Implications of zero suicide for suicide prevention research.
JAMA. 2018;320(16):1633-1634. doi:10.1001/jama.2018.13083
Reducing the Burden of Fellowship Interviews
To the Editor The Viewpoint by Dr Melcher and colleagues1
raised concerns regarding time expenditures, incurred costs,
and loss of clinical coverage caused by interviewing for sur-
gical fellowships and proposed an interview match as a way
to decrease the overall amount of interviews. They refer-
enced a survey of pediatric surgery program directors that
showed the median rank at which programs matched was
less than 4.2 There is a flaw in this justification: one cannot
assume that the top 4 candidates on a rank list were all appli-
cants who would have been granted interviews through an
interviewmatch.
I echo the authors’ concerns that such a system would
unfairly favor candidates who look good on paper and con-
verselycouldbedetrimental tocandidateswhoexcel inpersonal
interviews. Likewise, it would not allow for the serendipitous
connection between an applicant and representatives from
a program.
Technology may provide an alternative strategy to
decrease the time and expense of interviews. Telephone
interviews have been used in other disciplines as a less
expensive alternative to the traditional interview process.
After an application is received, telephone interviews might
be used as an additional screening prior to or in place of the
interview process. This would allow for a true interaction
between an applicant and representatives from a program in
an efficient, less costly manner.
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To the EditorDrMelcher and colleagues1 accurately described
the challenges of the current surgical fellowship application
systemandproposed amatchwithin thematch solution. The
essenceof their proposal centers on limiting thenumberof in-
terviews that an applicant can participate in and that pro-
grams can conduct.
Before adopting the interviewmatch systemproposedby
the authors, other approaches should be considered. Indus-
trial organizational psychology (the science of human behav-
ior related towork)may suggest a solution. Industrial organi-
zationalpsychologistsconduct researchonemployeebehaviors
and attitudes and how these can be improved through hiring
practices and training programs. Other high-risk professions
and most Fortune 500 companies use industrial organiza-
tional psychologists to improve personnel selection by their
organizations.2
Industrial organizational psychology suggests that there
are2problemswith the current surgical training selectionpro-
cess. First, applicants lack information that canhelp themde-
termine their fit into a program and candidacy for selection.
Second, programs lack tools that credibly separate one can-
didate from another.3 As a result, applicants cast a wide net
to improve their chances of selection, and programs conduct
many interviews to try to obtain more information. Indus-
trial organizational psychology would suggest that candi-
dates complete prescreening assessments (situational judg-
ment tests, personality profiles, integrity tests, etc) that
evaluate competencies identified to be required for success in
the position. The results would then be used by programs to
determine who to invite to interview.
Some surgery programs have worked with industrial or-
ganizational psychologists to address the problems associ-
ated with interviewing for fellowships. Preliminary studies
haveshownimprovedefficiency,a reduction in interviewnum-
bers, improvedcandidate satisfaction, and improvement in the
diversity of candidates considered.4,5
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